The 21 most recent market catalysts affecting $ALNY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
This filing reports that HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a 'Buy' rating for Alnylam Pharmaceuticals (ALNY) and maintained a $455 price target. This a…
Sep 2, 2026
Market Technicals
Neutral
Impact 55
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights unusual options activity, often indicative of institutional investors ('whales') taking significant positions. This matters because such large trades can sign…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio has reaffirmed a 'Buy' rating and a $455 price target for Alnylam Pharmaceuticals. This is a routine analyst update, indicating that…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Reported Earlier, Alnylam Highlights AMVUTTRA Results And New RNAi Approach For High Blood Pressure
Alnylam Pharmaceuticals announced new data at the ESC Congress 2026, showcasing the strength of its RNAi platform for cardiovascular disease. The findings reinforce AMVUTTRA's clin…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Alnylam Pharmaceuticals shares are trading higher after BMO Capital initiated coverage on the stock with a Outperform rating and announced a $318 price target.
This headline represents a significant corporate catalyst for Alnylam Pharmaceuticals. Analyst upgrades from reputable firms like BMO Capital often lead to immediate positive price…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
The filing announces new analyst coverage for five companies, with BMO Capital's David Lebowitz initiating on three of them. For Alnylam Pharmaceuticals (ALNY), Biomarin Pharmaceut…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318
BMO Capital's initiation of coverage on Alnylam Pharmaceuticals with an 'Outperform' rating and a $318 price target is a positive development for the company. This signals that a p…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420
Raymond James analyst Martin Auster upgraded Alnylam Pharmaceuticals (ALNY) from Outperform to Strong Buy, while simultaneously maintaining a $420 price target. This action signals…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 65
Alnylam Pharmaceuticals shares are trading higher. Barclays maintained its Overweight rating on the stock and lowered its price target from $527 to $450.
The headline indicates a positive market reaction for Alnylam Pharmaceuticals (ALNY) despite a price target reduction. This suggests that the maintained 'Overweight' rating from Ba…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450
Barclays analyst Eliana Merle maintained an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's fundamentals and future growth. However,…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $375
JP Morgan analyst Jessica Fye maintained an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's fundamentals and future performance. How…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 60
RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350
RBC Capital's decision to lower Alnylam Pharmaceuticals' price target by nearly 21% from $445 to $350, despite maintaining an 'Outperform' rating, indicates a reassessment of the c…
Jul 31, 2026
Corporate Catalyst
Neutral
Impact 65
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $300
Morgan Stanley analyst Michael Ulz lowered the price target for Alnylam Pharmaceuticals (ALNY) from $400 to $300, while maintaining an 'Equal-Weight' rating. This action indicates …
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 65
Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $350
Oppenheimer analyst Kostas Biliouris maintained an 'Outperform' rating on Alnylam Pharmaceuticals but drastically cut the price target from $500 to $350. This action indicates that…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam Pharmaceuticals announced a reduction in its fiscal 2026 sales guidance, primarily due to a slowdown in the growth of second-line Amvuttra demand in the ATTR-CM market, whi…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Alnylam Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for Alnylam Pharmaceuticals (ALNY). The combination of mixed Q2 results and, more critically, a cut in the FY26 sales guid…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est
Alnylam Pharmaceuticals announced a reduction in its financial year 2026 sales guidance. The new range of $5.275 billion-$5.725 billion is lower than the previous $5.300 billion-$5…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate
Alnylam Pharmaceuticals (ALNY) released its Q2 earnings, reporting an adjusted EPS of $1.84, which comfortably surpassed the analyst consensus of $1.55. This represents a remarkabl…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400
JP Morgan analyst Jessica Fye has reiterated an 'Overweight' rating on Alnylam Pharmaceuticals, signaling continued confidence in the company's long-term prospects. However, the ac…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Alnylam Highlights Neuroscience Progress At AAIC 2026, Initiating Phase 2 APPlauDS Study Of Mivelsiran In Down Syndrome-Associated Alzheimer's While Completing cAPPricorn-1 Enrollment In CAA
Alnylam has announced significant progress in its neuroscience pipeline for Mivelsiran, a key investigational drug. The initiation of a global Phase 2 study for Mivelsiran in Down …
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $485
HC Wainwright & Co. maintaining a 'Buy' rating and raising the price target for Alnylam Pharmaceuticals from $470 to $485 signals a positive outlook from a key analyst. This action…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.